高度リンパ節転移を伴う進行胃癌に対する周術期 Capecitabine＋Oxaliplatin療法の第II相試験（OGSG1701）

An intergroup phase III RINDBeRG trial: ramucirumab plus irinotecan beyond PD after ramucirumab

The intergroup phase III RINDBeRG Trial; Ramucirumab plus irinotecan beyond PD after ramucirumab for gastric cancer

A phase II study of perioperative capecitabine plus oxaliplatin (CapeOx) therapy for advanced gastric cancer with multiple lymph node metastases (OGSG 1701)

Subgroup analyses of the effect of ramucirumab in pretreatment with immune checkpoint inhibitor in RINDBeRG: a randomized clinical trial in third or further-line treatment of gastric cancer

The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG Trial).

Stage III胃癌に対する術後補助化学療法におけるS-1+docetaxelの投与サイクル数が長期生存に及ぼす影響

腹膜転移の病勢制御を考えたFU選択-進行胃癌1次治療におけるSP対XPの無作為化試験のメタ解析からの考察

Effect of number of cycles of S-1+docetaxel in adjuvant chemotherapy for Stage III gastric cancer